Market revenue in 2023 | USD 66.5 million |
Market revenue in 2030 | USD 108.4 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Overactive bladder |
Fastest growing segment | Overactive Bladder |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Overactive Bladder, Neurogenic Detrusor Overactivity |
Key market players worldwide | AbbVie Inc, Merz Pharma, Ipsen SA, Galderma Group AG Registered Shares, Allergan, Sun Pharmaceutical Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to botulinum toxin in urology market will help companies and investors design strategic landscapes.
Overactive bladder was the largest segment with a revenue share of 67.37% in 2023. Horizon Databook has segmented the China botulinum toxin in urology market based on overactive bladder, neurogenic detrusor overactivity covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the China botulinum toxin in urology market, including forecasts for subscribers. This country databook contains high-level insights into China botulinum toxin in urology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account